Non Hodgkin Lymphoma Clinical Trial
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Summary
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
Eligibility Criteria
Inclusion Criteria:
Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.
Patients may have to have tumor biopsy before and after treatment.
Exclusion Criteria:
Prior stem cell or bone marrow transplant
Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse
Active or unstable cardiac disease or history of heart attack within 6 months
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Detroit Michigan, 48201, United States
New York New York, 10065, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19104, United States
How clear is this clinincal trial information?